Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria.

BACKGROUND Hyperphenylalaninemia is a common inherited metabolic disease that is due to phenylalanine hydroxylase deficiency, and at least half the affected patients have mild clinical phenotypes. Treatment with a low-phenylalanine diet represents a substantial psychosocial burden, but alternative treatments have not been effective. METHODS To explore the therapeutic efficacy of tetrahydrobiopterin, we performed a combined phenylalanine-tetrahydrobiopterin loading test and analyzed the in vivo rates of [13C]phenylalanine oxidation in 38 children with phenylalanine hydroxylase deficiency (age range, 1 day to 17 years). We assessed whether responsiveness to tetrahydrobiopterin was associated with specific genotypes, and we mapped mutations using a structural model of the phenylalanine hydroxylase monomer. RESULTS In 27 (87 percent) of 31 patients with mild hyperphenylalaninemia (10 patients) or mild phenylketonuria (21 patients), tetrahydrobiopterin significantly lowered blood phenylalanine levels. Phenylalanine oxidation was significantly enhanced in 23 of these 31 patients (74 percent). Conversely, none of the seven patients with classic phenylketonuria had a response to tetrahydrobiopterin as defined in this study. Long-term treatment with tetrahydrobiopterin in five children increased daily phenylalanine tolerance, allowing them to discontinue their restricted diets. Seven mutations (P314S, Y417H, V177M, V245A, A300S, E390G, and IVS4-5C-->G) were classified as probably associated with responsiveness to tetrahydrobiopterin, and six mutations (A403V, F39L, D415N, S310Y, R158Q, and I65T) were classified as potentially associated. Four mutations (Y414C, L48S, R261Q, and I65V) were inconsistently associated with this phenotype. Mutations connected to tetrahydrobiopterin responsiveness were predominantly in the catalytic domain of the protein and were not directly involved in cofactor binding. CONCLUSIONS Tetrahydrobiopterin responsiveness is common in patients with mild hyperphenylalaninemia phenotypes. Responsiveness cannot consistently be predicted on the basis of genotype, particularly in compound heterozygotes.

[1]  N. Blau,et al.  Tetrahydrobiopterin Responsiveness in Phenylketonuria. Two New Cases and a Review of Molecular Genetic Findings , 2002, Journal of Inherited Metabolic Disease.

[2]  M. Durán,et al.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency in Dutch neonates , 2001, Journal of Inherited Metabolic Disease.

[3]  R. Stevens,et al.  A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria , 2001, Journal of Inherited Metabolic Disease.

[4]  Z. Lukacs,et al.  Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations , 2002, European Journal of Pediatrics.

[5]  C. Scriver.  Why mutation analysis does not always predict clinical consequences: explanations in the era of genomics. , 2002, The Journal of pediatrics.

[6]  B. Ames,et al.  High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. , 2002, The American journal of clinical nutrition.

[7]  N. Blau,et al.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency: possible regulation of gene expression in a patient with the homozygous L48S mutation. , 2002, Molecular genetics and metabolism.

[8]  P. Waters,et al.  Homomeric and heteromeric interactions between wild-type and mutant phenylalanine hydroxylase subunits: evaluation of two-hybrid approaches for functional analysis of mutations causing hyperphenylalaninemia. , 2001, Molecular genetics and metabolism.

[9]  E. Mayatepek,et al.  Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. , 2001, Molecular genetics and metabolism.

[10]  N. Blau,et al.  Successful treatment of phenylketonuria with tetrahydrobiopterin , 2001, European Journal of Pediatrics.

[11]  H. Möller,et al.  Normal Clinical Outcome in Untreated Subjects with Mild Hyperphenylalaninemia , 2001, Pediatric Research.

[12]  S. Kaufman,et al.  Mutagenesis of the regulatory domain of phenylalanine hydroxylase. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Guldberg,et al.  In vitro expression of 34 naturally occurring mutant variants of phenylalanine hydroxylase: correlation with metabolic phenotypes and susceptibility toward protein aggregation. , 2001, Molecular genetics and metabolism.

[14]  N. Blau,et al.  Tetrahydrobiopterin biosynthesis, regeneration and functions. , 2000, The Biochemical journal.

[15]  R. Stevens,et al.  Crystal structure and site-specific mutagenesis of pterin-bound human phenylalanine hydroxylase. , 2000, Biochemistry.

[16]  C R Scriver,et al.  PAHdb: A locus‐specific knowledgebase , 2000, Human mutation.

[17]  R. Stevens,et al.  The structural basis of phenylketonuria. , 1999, Molecular genetics and metabolism.

[18]  S. Kure,et al.  Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. , 1999, The Journal of pediatrics.

[19]  C R Scriver,et al.  Monogenic traits are not simple: lessons from phenylketonuria. , 1999, Trends in genetics : TIG.

[20]  R. Stevens,et al.  Structural basis of autoregulation of phenylalanine hydroxylase , 1999, Nature Structural Biology.

[21]  R. Stevens,et al.  Structure of Tetrameric Human Phenylalanine Hydroxylase and Its Implications for Phenylketonuria* , 1998, The Journal of Biological Chemistry.

[22]  P. Guldberg,et al.  A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. , 1998, American journal of human genetics.

[23]  C. Scriver.  An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria. , 1998, The Journal of clinical investigation.

[24]  A. Schaffner,et al.  Modulation of inducible nitric oxide synthase mRNA stability by tetrahydrobiopterin in vascular smooth muscle cells. , 1998, Biochemical and biophysical research communications.

[25]  P. Waters,et al.  In vitro expression analysis of mutations in phenylalanine hydroxylase: Linking genotype to phenotype and structure to function , 1998, Human mutation.

[26]  P. Waters,et al.  Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations. , 1997, American journal of human genetics.

[27]  R. Stevens,et al.  Crystal structure of the catalytic domain of human phenylalanine hydroxylase reveals the structural basis for phenylketonuria , 1997, Nature Structural Biology.

[28]  P. Waters,et al.  Analysis of Phenylalanine Hydroxylase Genotypes and Hyperphenylalaninemia Phenotypes Using L-[1-13C]Phenylalanine Oxidation Rates in Vivo: A Pilot Study1 , 1997, Pediatric Research.

[29]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[30]  H. Kacser,et al.  The control of flux. , 1995, Biochemical Society transactions.

[31]  S. Kaufman,et al.  The phenylalanine hydroxylating system. , 2006, Advances in enzymology and related areas of molecular biology.

[32]  P. Bosco,et al.  Mutational spectrum of phenylalanine hydroxylase deficiency in Sicily: implications for diagnosis of hyperphenylalaninemia in southern Europe. , 1993, Human molecular genetics.

[33]  F. Güttler,et al.  Molecular basis of phenotypic heterogeneity in phenylketonuria. , 1991, The New England journal of medicine.

[34]  P. Rutgeerts,et al.  Mixed triglyceride breath test: a noninvasive test of pancreatic lipase activity in the duodenum. , 1989, Gastroenterology.

[35]  G. Schwartz,et al.  Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. , 1978, The Journal of pediatrics.

[36]  R. Cotton,et al.  TETRAHYDROBIOPTERIN TREATMENT OF VARIANT FORM OF PHENYLKETONURIA , 1975, The Lancet.

[37]  S. Kaufman,et al.  The stimulation of rat liver phenylalanine hydroxylase by lysolecithin and -chymotrypsin. , 1973, The Journal of biological chemistry.